BioInvent International AB (LTS:0H22) Other Operating Expense : kr-0.29 Mil (TTM As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is BioInvent International AB Other Operating Expense?

BioInvent International AB's Other Operating Expense for the three months ended in Dec. 2024 was kr0.25 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was kr-0.29 Mil.

BioInvent International AB's quarterly Other Operating Expense declined from Jun. 2024 (kr-0.14 Mil) to Sep. 2024 (kr-0.37 Mil) but then increased from Sep. 2024 (kr-0.37 Mil) to Dec. 2024 (kr0.25 Mil).

BioInvent International AB's annual Other Operating Expense increased from Dec. 2022 (kr-0.08 Mil) to Dec. 2023 (kr-0.02 Mil) but then declined from Dec. 2023 (kr-0.02 Mil) to Dec. 2024 (kr-0.10 Mil).

BioInvent International AB Other Operating Expense Historical Data

The historical data trend for BioInvent International AB's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB Other Operating Expense Chart

BioInvent International AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Operating Expense

Get a 7-Day Free Trial

-1.25

-0.23

-0.08

-0.02

-0.10

BioInvent International AB Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Operating Expense	Get a 7-Day Free Trial															-0.49	-0.03	-0.14	-0.37	0.25

BioInvent International AB Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.29 Mil.

BioInvent International AB Other Operating Expense Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

BioInvent International AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (LTS:0H22) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

BINV:Sweden BIX0:Germany

Address

Ideongatan 1, Lund, SWE, SE-223 70

Website

https://www.bioinvent.com

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines